Clinical Grip Training and Assessment Tool for Rheumatoid Arthritis

BAM Innovation和Optima Design将共同设计一种针对类风湿性关节炎(RA)的颠覆性治疗和监测设备：GRIP-RA。目前迫切需要替代方法来支持这种影响全球2300万人的无法治愈的自身免疫性疾病的患者，三分之一的RA患者在确诊后五年内停止工作，用于治疗这种疾病的生物药物极其昂贵，需要根据疾病活动的变化定制剂量。该项目将设计一种创新设备，促进患者参与、监测和病情管理。GRIP-RA被设想为一个物理“压力球”式接口，带有嵌入式传感器，提供黄金标准的物理康复益处，同时捕获丰富的客观和患者报告的数据，以支持患者和临床医生更好的病情管理。它的简单界面将是直观的、以客户为中心的、可访问的，包括那些患有严重RA的人。患者和临床医生呼吁非智能手机的方法，这是出了名的患者依从性很差。BAMS的两位董事对RA有个人兴趣，具有深入的特定条件知识，特别是考虑到患者的角度。本项目将基于这些知识设计一种新的康复工具，以一种方式将患者和临床实践联系起来，为用户提供更明确的好处。我们的主要目标是研究GRIP-RA产品的商业吸引力和设计可行性。我们将深入研究潜在市场。与潜在客户的密切接触将告知我们他们的需求，并为设计过程提供信息。这将使我们能够生产由客户需求(例如临床医生/信托和制药公司)驱动的产品设计(CAD+模型)，并由Bath风湿病研究所慈善机构协助RA患者共同开发/评估。BAM将通过能够进入英国/全球RA市场而受益，全球类风湿性关节炎药物市场是重要的，预计到2027年将达到630亿美元，并提供了多种机会来发展采用我们技术的合作伙伴关系。例如，我们建议与一家领先的临床家庭护理/专业药房提供商建立探索性伙伴关系。主要的外部受益者是临床医生和患者本身，他们将获得更好的康复/治疗，减少痛苦，并支持更好地参与社会和经济。

BAM Innovation and Optima Design will co-design a disruptive treatment and monitoring device for rheumatoid arthritis (RA): Grip-RA.There is a desperate need for alternative approaches to support patients with this incurable autoimmune disease affecting \>23m people worldwide, with one-third of people with RA stopping working within five years of diagnosis and the biologic drugs used to manage the condition being extremely expensive, with dosages needing tailoring based on changes in disease activity.This project will design an innovative device which facilitates patient engagement, monitoring and condition management. Grip-RA is envisaged as a physical "stress-ball" style interface, with embedded sensors, offering gold-standard physical rehabilitation benefits, whilst capturing rich objective and patient-reported data to support better condition management for patients and clinicians. Its simple interface will be intuitive, customer-focused, and accessible, including to those with severe RA. Patients and clinicians are calling out for non-smartphone based approaches, which have notoriously poor patient adherence.BAMs two Directors have a personal interest in RA with deep condition specific knowledge, particularly considering the patient perspective.This project will build on this knowledge to design a new class of rehabilitative tool that links patient and clinical practice in a fashion which offers far clearer benefit to the user.Our main objectives are to research both the commercial pull and design feasibility of the Grip-RA product. We will research potential markets in depth. Close engagement with potential clients will inform us about their needs and inform the design process. This will allow us to produce product designs (CAD + model) driven by customer needs (e.g. clinicians/trusts and pharma) and co-developed/assessed by RA sufferers facilitated by the Bath Institute of Rheumatic Diseases charity.BAM will benefit through being able to enter UK/global RA markets, The global rheumatoid arthritis drugs market is significant, projected to reach $63bn by 2027 and presents multiple opportunities to develop partnerships deploying our technology. An example is our proposed exploratory partnership with a leading clinical home-care/specialist pharmacy provider.Key external beneficiaries are clinicians receiving better patient data and patients themselves, who will receive better rehabilitation/treatment reducing suffering and supporting better engagement with society and the economy.